Published in Curr Med Chem on January 01, 2014
From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov (2015) 0.85
Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. Nanomedicine (2015) 0.82
A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology (2017) 0.78
Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. J Clin Invest (2017) 0.77
Efficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdA. PLoS One (2016) 0.77
Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy. PLoS One (2015) 0.76
Development of NanoART for HIV Treatment: Minding the Cytochrome P450 (CYP) Enzymes. J Pers Nanomed (2015) 0.75
Investigational protease inhibitors as antiretroviral therapies. Expert Opin Investig Drugs (2016) 0.75
Poly(lactic-co-glycolic) Acid-Chitosan Dual Loaded Nanoparticles for Antiretroviral Nanoformulations. J Drug Deliv (2016) 0.75
Antiretroviral Drugs-Loaded Nanoparticles Fabricated by Dispersion Polymerization with Potential for HIV/AIDS Treatment. Infect Dis (Auckl) (2016) 0.75
Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS. Nanomedicine (Lond) (2016) 0.75
Hydrophobic-core PEGylated graft copolymer-stabilized nanoparticles composed of insoluble non-nucleoside reverse transcriptase inhibitors exhibit strong anti-HIV activity. Nanomedicine (2016) 0.75
Emerging Nanomedicine Approaches to Targeting HIV-1 and Antiretroviral Therapy. Future Virol (2016) 0.75
Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv (2017) 0.75
The therapeutic landscape of HIV-1 via genome editing. AIDS Res Ther (2017) 0.75
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
The role of mononuclear phagocytes in HTLV-III/LAV infection. Science (1986) 17.33
Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol (1969) 10.33
Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol (1989) 9.37
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
The dawning era of polymer therapeutics. Nat Rev Drug Discov (2003) 7.86
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med (1991) 7.01
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
The neuropathogenesis of AIDS. Nat Rev Immunol (2005) 6.54
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Sequence-specific RNA binding by the HIV-1 Rev protein. Nature (1989) 5.36
The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med (2002) 4.73
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm (2000) 4.68
Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A (1989) 4.66
Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol (1990) 4.35
In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). J Immunol (1986) 4.12
The cell biology of the blood-brain barrier. Annu Rev Neurosci (1999) 3.60
Structural and functional characterization of human immunodeficiency virus tat protein. J Virol (1989) 3.57
Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol (1990) 3.42
Transferrin receptor on endothelium of brain capillaries. Nature (1984) 3.37
Human immunodeficiency virus detected in bowel epithelium from patients with gastrointestinal symptoms. Lancet (1988) 3.21
Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl (2006) 3.07
HIV dementia: an evolving disease. J Neuroimmunol (2004) 2.88
Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol (1987) 2.84
Antiretroviral therapy and management of HIV infection. Lancet (2010) 2.84
Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem (2005) 2.32
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood (2006) 2.13
Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol (2009) 1.85
Drug delivery to the central nervous system: a review. J Pharm Pharm Sci (2003) 1.76
NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) (2009) 1.72
Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother (2002) 1.63
Analysis of lymphopoietic stem cells with a monoclonal antibody to the rat transferrin receptor. Immunology (1985) 1.62
Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release (2004) 1.59
NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond) (2009) 1.55
Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis (2000) 1.51
HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin (2008) 1.50
A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood (2008) 1.49
HIV-1 replication. Somat Cell Mol Genet (2001) 1.45
Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med (2008) 1.45
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol (2010) 1.42
Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology (2006) 1.41
Neurocognitive disturbances in HIV. Int Rev Psychiatry (2008) 1.38
A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug Chem (2007) 1.38
Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm Res (1999) 1.35
Cell-mediated drug delivery. Expert Opin Drug Deliv (2011) 1.33
Targeted drug delivery via folate receptors. Expert Opin Drug Deliv (2008) 1.33
Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS (2012) 1.32
Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the blood-brain barrier. Int J Nanomedicine (2010) 1.31
Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release (1999) 1.29
HIV infection and the gastrointestinal tract. AIDS (2005) 1.26
Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep (2011) 1.26
Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J (2007) 1.25
Human immunodeficiency virus infection of enterocytes and mononuclear cells in human jejunal mucosa. Gastroenterology (1991) 1.23
Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J Infect Dis (2012) 1.23
Acute primary HIV infection. JAMA (1997) 1.22
Emerging nanopharmaceuticals. Nanomedicine (2008) 1.21
Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. Clin Infect Dis (2001) 1.21
Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine (2013) 1.21
Folate-decorated nanogels for targeted therapy of ovarian cancer. Biomaterials (2011) 1.21
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med (1998) 1.19
Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob Agents Chemother (2013) 1.17
Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res (1999) 1.16
Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev (2009) 1.15
Redistribution of HIV outside the lymphoid system with onset of AIDS. Lancet (1994) 1.14
Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J Drug Target (2007) 1.14
Mononuclear phagocytes as targets, tissue reservoirs, and immunoregulatory cells in human immunodeficiency virus disease. Curr Top Microbiol Immunol (1992) 1.12
Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (Lond) (2010) 1.12
Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain (2003) 1.11
Dendrimers: emerging polymers for drug-delivery systems. Eur J Pharm Sci (2009) 1.11
Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther (2008) 1.11
Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers. Life Sci (1996) 1.09
Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. Int J Nanomedicine (2012) 1.08
Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci (2010) 1.07
Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother (2010) 1.07
In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine (2011) 1.05
Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond) (2010) 1.04
A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res (2006) 1.04
Brain uptake of thiamine-coated nanoparticles. J Control Release (2003) 1.03
Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res (2008) 1.02
In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur J Pharm Sci (2002) 1.01
In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharm Res (2003) 1.01
Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm Res (2006) 0.99
Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res (2000) 0.99
Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. Adv Drug Deliv Rev (2009) 0.99
Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine (2008) 0.99
Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim Biophys Acta (2006) 0.99
Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim Biophys Acta (2002) 0.98
In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull (Tokyo) (2001) 0.98
Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery. Int J Pharm (2012) 0.98
Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev (2009) 0.97
Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J Cereb Blood Flow Metab (2006) 0.97
Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res (2000) 0.96
Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm (2007) 0.95
CNS drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul (2009) 0.95
Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Deliv (2006) 0.94
Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol (2009) 1.85
Greenhouse and field testing of transgenic wheat plants stably expressing genes for thaumatin-like protein, chitinase and glucanase against Fusarium graminearum. J Exp Bot (2003) 1.81
Click chemistry, a powerful tool for pharmaceutical sciences. Pharm Res (2008) 1.67
DJ-1 decreases Bax expression through repressing p53 transcriptional activity. J Biol Chem (2007) 1.59
The correlation of in vivo and ex vivo tissue dielectric properties to validate electromagnetic breast imaging: initial clinical experience. Physiol Meas (2009) 1.22
Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res Ther (2007) 1.21
Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine (2013) 1.21
Heparin-loaded zein microsphere film and hemocompatibility. J Control Release (2005) 1.17
Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob Agents Chemother (2013) 1.17
Osteotropic Peptide that differentiates functional domains of the skeleton. Bioconjug Chem (2007) 1.17
Novel thienopyridine derivatives as specific anti-hepatocellular carcinoma (HCC) agents: synthesis, preliminary structure-activity relationships, and in vitro biological evaluation. Bioorg Med Chem Lett (2010) 1.05
Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience. Breast Cancer Res (2013) 1.05
Identification of surrogate agonists and antagonists for orphan G-protein-coupled receptor GPR139. J Biomol Screen (2009) 0.97
Clinical microwave tomographic imaging of the calcaneus: a first-in-human case study of two subjects. IEEE Trans Biomed Eng (2012) 0.92
A homogeneous G protein-coupled receptor ligand binding assay based on time-resolved fluorescence resonance energy transfer. Assay Drug Dev Technol (2008) 0.92
Pharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugates in adjuvant-induced arthritis rat model. Mol Pharm (2010) 0.92
Synthesis, structure-activity relationships and preliminary antitumor evaluation of benzothiazole-2-thiol derivatives as novel apoptosis inducers. Bioorg Med Chem Lett (2010) 0.89
NMR-based metabonomic study of the sub-acute toxicity of titanium dioxide nanoparticles in rats after oral administration. Nanotechnology (2010) 0.89
Triclosan-loaded tooth-binding micelles for prevention and treatment of dental biofilm. Pharm Res (2010) 0.84
Covalent binding of the flavonoid quercetin to human serum albumin. J Agric Food Chem (2005) 0.84
Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands. Biochem J (2009) 0.83
Tooth-binding micelles for dental caries prevention. Antimicrob Agents Chemother (2009) 0.83
Tablets based on compressed zein microspheres for sustained oral administration: design, pharmacokinetics, and clinical study. J Biomater Appl (2010) 0.81
Small magnetite antiretroviral therapeutic nanoparticle probes for MRI of drug biodistribution. Nanomedicine (Lond) (2013) 0.81
Application of cryopreserved human hepatocytes in trichloroethylene risk assessment: relative disposition of chloral hydrate to trichloroacetate and trichloroethanol. Environ Health Perspect (2006) 0.81
Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity. J Proteome Res (2013) 0.81
Microwave thermal imaging of scanned focused ultrasound heating: phantom results. Int J Hyperthermia (2008) 0.81
Bone dielectric property variation as a function of mineralization at microwave frequencies. Int J Biomed Imaging (2012) 0.81
A novel anticancer agent, SKLB70359, inhibits human hepatic carcinoma cells proliferation via G0/G1 cell cycle arrest and apoptosis induction. Cell Physiol Biochem (2012) 0.79
The synthesis of a multiblock osteotropic polyrotaxane by copper(I)-catalyzed huisgen 1,3-dipolar cycloaddition. Macromol Biosci (2010) 0.78
Directed self-assembly of nanoparticles for nanomotors. ACS Nano (2013) 0.78
Effect of R(+)alpha-lipoic acid on pyruvate metabolism and fatty acid oxidation in rat hepatocytes. Metabolism (2004) 0.77
Bench-to-bedside translation of magnetic nanoparticles. Nanomedicine (Lond) (2014) 0.77
HMGB1Modulates the Treg/Th17 Ratio in Atherosclerotic Patients. J Atheroscler Thromb (2016) 0.77
Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues. Nanomedicine (Lond) (2014) 0.76
The effects of galangin on a mouse model of vitiligo induced by hydroquinone. Phytother Res (2014) 0.76
Induction of peroxisome proliferation in cultured hepatocytes by a series of halogenated acetates. Toxicology (2004) 0.76
Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine. J Acquir Immune Defic Syndr (2016) 0.76
Polymeric nanoarchitectures on Ti-based implants for antibacterial applications. ACS Appl Mater Interfaces (2014) 0.76
Isatin Derived Spirocyclic Analogues with α-Methylene-γ-butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study. J Med Chem (2016) 0.76
Photo-sensitive liposomes: chemistry and application in drug delivery. Mini Rev Med Chem (2010) 0.75
4,6-Dinitro-benzene-1,3-diamine. Acta Crystallogr Sect E Struct Rep Online (2008) 0.75
N-Acetyl-5-chloro-3-nitro-l-tyrosine ethyl ester. Acta Crystallogr Sect E Struct Rep Online (2012) 0.75
Microwave tomography in the context of complex breast cancer imaging. Conf Proc IEEE Eng Med Biol Soc (2010) 0.75
Age-specific effects of P2X7 receptors on olfactory function in mice. Neuroreport (2019) 0.75
Stepwise assembly of a cross-linked free-standing nanoparticle sheet with controllable shape. Nanoscale (2015) 0.75
Novel benzothiazole, benzimidazole and benzoxazole derivatives as potential antitumor agents: synthesis and preliminary in vitro biological evaluation. Molecules (2012) 0.75
Spectral focusing dual-comb coherent anti-Stokes Raman spectroscopic imaging. Opt Lett (2017) 0.75
Improved system calibration for specular surface measurement by using reflections from a plane mirror. Appl Opt (2016) 0.75
Tn5 transposase-assisted high-efficiency transformation of filamentous fungus Phoma herbarum YS4108. Appl Microbiol Biotechnol (2008) 0.75
Catalytic Dehydrogenative C-C Coupling by a Pincer-Ligated Iridium Complex. J Am Chem Soc (2017) 0.75
[Determination of isomerized alpha-acids in beer using solid phase extraction-high performance liquid chromatography]. Se Pu (2007) 0.75
SKLB70326, a novel small-molecule inhibitor of cell-cycle progression, induces G₀/G₁ phase arrest and apoptosis in human hepatic carcinoma cells. Biochem Biophys Res Commun (2012) 0.75
Automated detection of cloud and aerosol features with SACOL micro-pulse lidar in northwest China. Opt Express (2017) 0.75
Film from peroxidation of an amino phospholipid and its biocompatibility. J Biomed Mater Res B Appl Biomater (2006) 0.75
Directed self-assembly of hetero-nanoparticles using a polymer single crystal template. Nanoscale (2012) 0.75
Synthesis, antiproliferative activities and in vitro biological evaluation of novel benzofuransulfonamide derivatives. Bioorg Med Chem Lett (2011) 0.75
Improved method for rapid shape recovery of large specular surfaces based on phase measuring deflectometry. Appl Opt (2016) 0.75
Gram-scale synthesis of superparamagnetic Fe3O4 nanocrystal clusters with long-term charge stability for highly stable magnetically responsive photonic crystals. Nanoscale (2016) 0.75
[Influence of topiramate on physical growth during treatment of children with epilepsy]. Zhonghua Er Ke Za Zhi (2005) 0.75